Bju International | 2021
COVID‐19 vaccines for rapid global impact
Abstract
Writing in early January 2021, less than a year from the disclosure of the SARS-CoV-2 coronavirus genome sequence, it is truly extraordinary that three vaccines have been developed, with impressive efficacy results published [1–3], licensure confirmed in many countries, and these are being administered to millions of people to help contain the worst pandemic for over a century. Three other vaccines, from Russia and China [4–6], are also being deployed and likely to have similar high efficacy and two further vaccines [7,8] from Janssen and Novavax are completing phase III trials. This editorial aims to the review some of this progress with a focus on the Oxford/ AstraZeneca vaccine which, the Jenner Institute has been centrally involved with.